磷酸二苯酯银(1+)盐 | 22350-95-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 中文名称: 磷酸二苯酯银(1+)盐
• 英文名称: Phosphoric acid, silver(1+) salt
• 英文别名: diphenyl hydrogen phosphate;silver
• CAS: 22350-95-4
• 化学式: C12H11AgO4P
• 分子量: 358.05
• InChiKey: WQBUKMYKNIUKDT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.24
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Prodrug compounds and their uses
  申请人：LIGAND PHARMACEUTICALS, INC.

  公开号：US10449210B2

  公开（公告）日：2019-10-22

  Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.

  本文提供的是原药化合物、其制备方法及其用途，例如通过干预肝脏中的分子通路来治疗肝脏疾病或非肝脏疾病。本文描述了酸/醇衍生物（如磷酸盐、膦酸盐、磷酰胺盐、磷酰胺盐、羧酸盐、苯酚盐和烷氧基盐）的新型原药化合物、其制备方法及其用途。本文所述的一些新型原药化合物在活化过程中不会产生乙烯酮反应中间体。另一个方面包括使用原药治疗疾病，这些疾病可受益于药物在肝脏及类似组织和细胞中的分布增强。
• PRODRUG COMPOUNDS AND THEIR USES
  申请人：Ligand Pharmaceuticals, Inc.

  公开号：EP3105238A1

  公开（公告）日：2016-12-21
• [EN] PRODRUG COMPOUNDS AND THEIR USES<br/>[FR] COMPOSÉS DE PROMÉDICAMENTS ET LEURS UTILISATIONS
  申请人：LIGAND PHARM INC

  公开号：WO2015123352A1

  公开（公告）日：2015-08-20

  Provided herein are prodrug compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in molecular pathways in the liver. Novel prodrug compounds of acid/alcohol derivatives such as phosphates, phosphonates, phosphonamidates, phosphoramidates, carboxylates, phenolates, and alkoxylates, their preparation and their uses are described. Some of the novel prodrug compounds described herein do not generate a vinyl keto reactive intermediate in the activation process. Another aspect includes the use of prodrugs to treat diseases that benefit from enhanced drug distribution to the liver and like tissues and cells.